Regulatory T Cell Identification Kit Using CD127 and CD25 Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for accurately identifying and quantifying regulatory T cells (Tregs) due to overlapping CD25 expression with antigen-experienced CD4+ T cells, leading to ambiguous results in autoimmune, immunoinflammatory, and allergic disease studies.
Innovation Solution
The method involves analyzing CD127, CD4, and CD25 expression levels to distinguish Tregs, using flow cytometry and immunoassays, and isolating CD127lowCD4+CD25+ cells, which is indicative of regulatory T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If CD25 expression is used to identify regulatory T cells, then Treg detection is simplified, but measurement precision deteriorates due to overlapping expression with activated/memory CD4+ T cells
Solution Approach 1:
The patent segments the CD4+ T cell population into distinct subsets by combining CD25 expression analysis with CD127 expression analysis and transcription factor profiling (FoxP3, RORγt, Tbet, GATA3). This segmentation allows differentiation between Tregs (CD25+CD127−FoxP3+) and activated/memory CD4+ T cells (CD25+CD127+), resolving the identification ambiguity while maintaining operational feasibility through standardized flow cytometry protocols
Solution Approach 2:
The patent introduces CD127 as an intermediary marker to bridge the gap between simple CD25-based detection and accurate Treg identification. CD127 expression status serves as a discriminating feature that mediates the distinction between Tregs and other CD25+ T cell subsets, enabling precise phenotypic characterization without complicating the overall detection workflow
2Measurement precision
If multiple markers (CD127, CD4, CD25) are analyzed to distinguish Tregs, then measurement precision improves, but device complexity increases
Solution Approach 1:
The patent employs a universal flow cytometry panel design where a single antibody cocktail simultaneously detects multiple markers (CD4, CD25, CD127) on the same cell population. This multi-functional approach enables comprehensive Treg phenotyping without requiring separate assays for each marker, thereby improving measurement precision while keeping the device complexity manageable through standardized protocols
Solution Approach 2:
The patent utilizes parameter changes in marker expression levels (particularly the differential expression patterns of CD25 and CD127) to distinguish Treg subsets from other T cell populations. By analyzing the combinatorial expression states of these markers rather than relying on single-marker thresholds, the method achieves high identification accuracy using conventional flow cytometry equipment without requiring complex specialized devices
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for precise identification and isolation of Tregs, reducing misinterpretation and providing clear separation from activated/memory CD4+ T cells, thereby improving diagnostic and therapeutic strategies for autoimmune and inflammatory diseases.
Implementation Method 1
Antibodies used for this purpose can be conjugated either directly or indirectly with a fluorochrome that emits a signal upon excitation with light of a certain wavelength. In this way, the presence and quantification of particular cell populations in a biological sample can be determined.
Implementation Method 2
Antibodies used for this purpose can be conjugated either directly or indirectly with a fluorochrome that emits a signal upon excitation with light of a certain wavelength.
Data Source
AI summary
The present invention relates to methods and kits for identifying, quantifying and isolating regulatory T cells, to methods and kits for diagnosing or monitoring autoimmune diseases, immunoinflammatory diseases, allergic diseases, predispositions thereto, infectious diseases, cancer, cancer treatment and/or organ transplantation based on regulatory T cell quantity, to methods and kits for predicting responses to therapy for autoimmune diseases, immunoinflammatory diseases, allergic diseases, predispositions thereto, infectious diseases, cancer and/or organ transplantation based on regulatory T cell quantity, and to methods and kits for therapy using isolated regulatory T cells.